Gilead Sciences, Inc. today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback